BlackRock
CABA icon

BlackRock’s Cabaletta Bio CABA Stock Holding History

BlackRock’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.4M Buy
10,754,701
+8,381,698
+353% +$27.6M ﹤0.01% 2924
2026
Q1 		$6.38M Buy
2,373,003
+44,533
+2% +$124K ﹤0.01% 3732
2025
Q4 		$5.1M Buy
2,328,470
+707,598
+44% +$1.75M ﹤0.01% 3834
2025
Q3 		$3.79M Buy
1,620,872
+650,271
+67% +$1.12M ﹤0.01% 3894
2025
Q2 		$1.48M Sell
970,601
-2,481,546
-72% -$3.87M ﹤0.01% 4144
2025
Q1 		$4.78M Buy
3,452,147
+54,887
+2% +$117K ﹤0.01% 3664
2024
Q4 		$7.71M Sell
3,397,260
-1,396,224
-29% -$4.9M ﹤0.01% 3550
2024
Q3 		$22.6M Buy
4,793,484
+37,265
+0.8% +$216K ﹤0.01% 2959
2024
Q2 		$35.6M Buy
4,756,219
+699,106
+17% +$8.57M ﹤0.01% 2618
2024
Q1 		$69.2M Sell
4,057,113
-351,892
-8% -$7.55M ﹤0.01% 2266
2023
Q4 		$100M Buy
4,409,005
+1,966,808
+81% +$33.1M ﹤0.01% 2074
2023
Q3 		$37.2M Buy
2,442,197
+732,479
+43% +$10M ﹤0.01% 2573
2023
Q2 		$22.1M Buy
1,709,718
+1,477,768
+637% +$16M ﹤0.01% 2983
2023
Q1 		$1.92M Sell
231,950
-30,355
-12% -$284K ﹤0.01% 4082
2022
Q4 		$2.43M Sell
262,305
-175,679
-40% -$640K ﹤0.01% 4055
2022
Q3 		$285K Sell
437,984
-60,807
-12% -$73.2K ﹤0.01% 4881
2022
Q2 		$529K Sell
498,791
-11,796
-2% -$16.7K ﹤0.01% 4762
2022
Q1 		$1.04M Buy
510,587
+6,397
+1% +$16.7K ﹤0.01% 4655
2021
Q4 		$1.91M Buy
504,190
+173,709
+53% +$1.85M ﹤0.01% 4421
2021
Q3 		$4.02M Buy
330,481
+13,293
+4% +$123K ﹤0.01% 4031
2021
Q2 		$2.73M Sell
317,188
-731,376
-70% -$7.19M ﹤0.01% 4136
2021
Q1 		$11.6M Buy
1,048,564
+97,168
+10% +$1.19M ﹤0.01% 3480
2020
Q4 		$11.9M Buy
951,396
+318,999
+50% +$4.14M ﹤0.01% 3278
2020
Q3 		$6.86M Buy
632,397
+9,714
+2% +$112K ﹤0.01% 3436
2020
Q2 		$6.94M Buy
622,683
+314,401
+102% +$2.41M ﹤0.01% 3386
2020
Q1 		$2.25M Buy
308,282
+70,744
+30% +$970K ﹤0.01% 3620
2019
Q4 		$3.32M Buy
+237,538
New +$2.81M ﹤0.01% 3625

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

BlackRock's CABA Position: Q2 2026 in Review

BlackRock increased its Cabaletta Bio (CABA) stake by 353% in Q2 2026, buying an estimated $27.6M and bringing the position to 10,754,701 shares worth $33.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2924.

BlackRock first reported a position in CABA in Q4 2019 and has held it in 27 quarters since. The position peaked at $100M in Q4 2023. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • BlackRock held 10,754,701 shares of Cabaletta Bio worth $33.4M as of Q2 2026.
  • BlackRock bought 8,381,698 Cabaletta Bio shares in Q2 2026, an estimated $27.6M.
  • Cabaletta Bio made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2924 holding.
  • BlackRock first reported a position in Cabaletta Bio in Q4 2019 and has held it in 27 quarters since.
  • BlackRock's Cabaletta Bio position peaked at $100M in Q4 2023.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.